ArticleJournal of liver cancer2024
Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives.
Article in Journal of liver cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study.Liver cancer · 2026Article
- The Role of the Multidisciplinary Team in the Management of Complex Cases of Liver Disease in a Peripheral Hospital: A Retrospective Analysis of MDT Registry.Health science reports · 2026Article
- Assessment prior to liver tumor resection: what a radiologist needs to know.Abdominal radiology (New York) · 2026Review
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- Hepatocellular Carcinoma at a Center of Clinical Excellence in Colombia: A Real-World Cohort Study of Clinical Characteristics, Treatment Trajectories, and Survival.Journal of hepatocellular carcinoma · 2026Article
- Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicenter study on overall and recurrence-free survival following liver resection or liver transplantation.Frontiers in immunology · 2026Article
- Integrating Network Pharmacology and Clinical Observation to Elucidate the Therapeutic Mechanisms of Yangzheng Xiaoji Decoction in Primary Liver Cancer.International journal of general medicine · 2026Article
- Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China.Frontiers in oncology · 2026Article
- Unusual bilateral lymphadenopathy revealing Hodgkin's lymphoma: a case report.Discover oncology · 2025Article
- Applying quality indicators and multidisciplinary team care to improve long-term survival in early-stage hepatocellular carcinoma.Asia-Pacific journal of oncology nursing · 2025Article
- Advancements in nanoultrasonics technology for the diagnosis and treatment of liver cancer: discussion on medical ethics and hospital management issues.Nanomedicine (London, England) · 2025Review
- Review
- Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma.Journal of liver cancer · 2025Article
- Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea.Journal of liver cancer · 2025Article
- Stemness-hypoxia genesTranslational cancer research · 2025Article
- Article
- Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.Clinical and molecular hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of hepatocellular carcinoma (HCC) is challenging due to the complex relationship between underlying liver disease, tumor burden, and liver function. HCC is also notorious for its high recurrence rate even after curative treatment for early-stage tumor. Liver transplantation can substantially alter patient prognosis, but donor availability varies by each patient which further complicates treatment decision. Recent advancements in HCC treatments have introduced numerous potentially efficacious treatment modalities. However, high level evidence comparing the risks and benefits of these options is limited. In this complex situation, multidisciplinary approach or multidisciplinary team care has been suggested as a valuable strategy to help cope with escalating complexity in HCC management. Multidisciplinary approach involves collaboration among medical and health care professionals from various academic disciplines to provide comprehensive care. Although evidence suggests that multidisciplinary care can enhance outcomes of HCC patients, robust data from randomized controlled trials are currently lacking. Moreover, the implementation of a multidisciplinary approach necessitates increased medical resources compared to conventional cancer care. This review summarizes the current evidence on the role of multidisciplinary approach in HCC management and explores potential future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.